[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ultra-high-field-7t\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ultra-high-field-7t":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100511432","new-imaging-biomarkers-predictive-of-ma-progression-100511432",false,"NCT05939362","New Imaging Biomarkers Predictive of MA Progression","Identifying Imaging Biomarkers Predictive of Disability Progression in Alzheimer's Disease: Pilot Study","MR7T-PRADA","Inclusion Criteria:\n\n* French-speaking patients aged 60 to 90 years,\n* Patient in the context of Alzheimer's disease \\* for which imaging after MRI is prescribed as part of the usual diagnostic process,\n\n  \\*Alzheimer's disease is diagnosed by the doctor of the memory consultation and is defined by :Evidence of a storage disorder in verbal episodic memory at LR\u002FRI defined by a sum of LR \\\u003C 17\u002F48 and sum of RT \\\u003C 40\u002F48 +\u002F- Impairment of executive functions possible (BREF, TMT grefex, verbal fluencies) +\u002F- Impairment of instrumental functions possible (Grémots noun naming, Rey's figure, Mahieux's Battery).\n* MMSE score ≥18,\n* Written informed consent after the patient has been informed,\n* Progressive decline for at least 6 months.\n\nExclusion Criteria:\n\n--Partially or completely illiterate patient unable to read and write,\n\n* Patient with an absolute contraindication to 7T MRI\n* Severe psychiatric pathology not balanced,\n* Non-degenerative neurological disease (stroke, multiple sclerosis ...),\n* Patient with tumor or inflammatory pathology, or vascular leukopathy visualized in MRI (Fazekas score \\> 3)","ALL","60 Years","90 Years",{"count":21,"type":22},80,"ESTIMATED","INTERVENTIONAL",[25],"NA","The pathophysiology of AD is complex. In addition to amyloid plaques and neurofibrillary degeneration, there is a metabolic alteration of the energy pathways, oxidative phosphorylation and glycolysis, which are involved in brain function. Several authors have shown a series of early metabolic dysregulations via an increase in phosphorylation at the origin of neuronal death.\n\nUltra-high field imaging (7T MRI) may allow, with its better spatial resolution and advanced imaging techniques, to shed light on the mechanisms of progression of Alzheimer's disease. A Magnetic Resonance Spectroscopy (MRS) examination can be coupled to brain MRI without additional risk for the patient. Multinuclear 1H-31P metabolic imaging is a promising tool that can provide information on the metabolic evolutionary profile of AD. Thus, we propose a longitudinal study in patients with early-stage AD on 7T MRI-MRS.",[28,29,30,31,32],"Alzheimer Disease","Magnetic Resonance Spectroscopy","Ultra High Field 7T","Progression of Disease","MR Biomarkers","RECRUITING","2024-12-05",{"date":36,"type":37},"2024-12-10","ACTUAL",{"date":39,"type":37},"2023-10-02",{"date":41,"type":22},"2028-01-15",{"name":43,"class":44},"Poitiers University Hospital","OTHER"]